Clemizole is a first-generation histamine H1 receptor antagonist with antihistaminic, moderate sedative, and pronounced antipruritic effects; it has been reported to prolong the effective refractory period of atrial myocardium and used in the treatment of atrial flutter; recent studies demonstrate its potential therapeutic efficacy against hepatitis C virus (HCV) infection by inhibiting HCV RNA replication through suppression of NS4B’s RNA binding; additionally, clemizole is a potent and selective inhibitor of TRPC5 ion channels, effectively blocking TRPC5 currents and Ca²⁺ entry with an IC₅₀ of 1.0–1.3 µM, showing significant selectivity over TRPC4β, TRPC3, and TRPC6.